RESUMEN
Respiratory emergencies in children are frequent and are caused by the specific airway anatomy and the susceptibility for infections.This article reviews the specific approach to pediatric airway management. According to the ABC guidelines of the European Resuscitation Council, the described algorithm should help to identify, classify, and treat such emergencies, giving those with less pediatric experience a tool for the management of respiratory illness in children. Focus is on the emergency care of the most common diseases in this age group.
Asunto(s)
Manejo de la Vía Aérea/métodos , Servicios Médicos de Urgencia/métodos , Insuficiencia Respiratoria/terapia , Algoritmos , Niño , Diagnóstico Diferencial , Servicios Médicos de Urgencia/ética , Ética Médica , Adhesión a Directriz/ética , Humanos , Comunicación Interdisciplinaria , Colaboración Intersectorial , Insuficiencia Respiratoria/diagnóstico , Insuficiencia Respiratoria/etiología , Resucitación/ética , Resucitación/métodosRESUMEN
BACKGROUND: Severe respiratory failure of the newborn requires adjunctive therapies as application of surfactant, inhalation of nitric oxide (iNO), high frequency oscillatory ventilation (HFOV), or extracorporeal membrane oxygenation (ECMO). We designed this study to analyze the the usage and effectiveness of adjunctive therapies and the mortality of severe respiratory failure. PATIENTS AND METHODS: The survey in Germany was done in collaboration with the "Erhebungseinheit für seltene pädiatrische Erkrankungen" (ESPED). 397 patients within 2 years were included into the study. Effectiveness of each adjunctive therapy was judged by the treating physician. RESULTS: The most frequent diagnosis was respiratory distress syndrome (RDS) with 36.8%, followed by pneumonia sepsis (16.4%), meconium aspiration syndrome (MAS) and congenital diaphragmatic hernia (CDH). Surfactant was applied in 77.3% of all cases with a reported effectiveness of 71.6%. More than 40% of all patients were treated with iNO, which led to an improvement in every second case. HFOV was used in every third case with a response rate of about 60%. ECMO was performed on one in 7 patients and was successful with a survival rate of nearly 80%. The overall mortality was 10.3%. 29 patients in total died without ECMO. 10 of them might actually have been contraindicated, but 19 cases with a potential benefit from ECMO were not transferred for ECMO. CONCLUSION: Our study-data suggests that more newborns suffering from respiratory failure should be transferred to centers offering ECMO.
Asunto(s)
Insuficiencia Respiratoria/terapia , Administración por Inhalación , Estudios de Cohortes , Terapia Combinada , Oxigenación por Membrana Extracorpórea , Femenino , Alemania , Encuestas de Atención de la Salud , Ventilación de Alta Frecuencia , Humanos , Recién Nacido , Masculino , Óxido Nítrico/administración & dosificación , Surfactantes Pulmonares/administración & dosificación , Insuficiencia Respiratoria/diagnóstico , Insuficiencia Respiratoria/mortalidad , Insuficiencia Respiratoria/fisiopatología , Encuestas y Cuestionarios , Tasa de Supervivencia , Resultado del TratamientoAsunto(s)
Enfisema Mediastínico/diagnóstico , Infecciones por Virus Sincitial Respiratorio/diagnóstico , Enfisema Subcutáneo/diagnóstico , Administración por Inhalación , Albuterol/administración & dosificación , Terapia Combinada , Diagnóstico Diferencial , Femenino , Humanos , Lactante , Enfisema Mediastínico/terapia , Terapia por Inhalación de Oxígeno , Admisión del Paciente , Infecciones por Virus Sincitial Respiratorio/terapia , Enfisema Subcutáneo/terapiaRESUMEN
OBJECTIVE: Advances in treatment of neonatal respiratory failure are responsible for a decline in the number of newborns treated with extracorporeal membrane oxygenation (ECMO). The aim of this study are to determine demographic changes, focusing on time of referral, diagnosis, and respiratory parameters in neonates put on ECMO. DESIGN: Retrospective review. SETTING: Tertiary ECMO center. PATIENTS: A total of 321 neonates were treated with ECMO from January 1987 to December 2006. RESULTS: Overall number of patients increased with every 5-year period, whereby congenital diaphragmatic hernia (CDH) was the most common diagnosis (53%), followed by meconium aspiration syndrome (MAS) (21%), sepsis and/or pneumonia (13%), and others such as persistent pulmonary hypertension of the newborn (PPHN), respiratory distress syndrome (RDS), or hypoplasia of the lung (13%). Worsening severity of illness as measured by ECMO duration and days on ventilator has to be stated for all diagnoses. Nevertheless, survival rate remained stable; both overall and diagnosis-specific mortality rates did not change significantly. Of all children, 67% survived to discharge or transfer, while best rates were seen for MAS (94%), followed by sepsis and/or pneumonia (69%), CDH (62%), and other diagnoses (43%). Concerning survival rate, no difference between inborn and outborn children occurred. However, between early- and late-referred children, a referral to the ECMO center during the first 24 h of life was associated with a significantly higher rate of survival (77% versus 54%, p = 0.0004), predominantly seen for CDH (67% versus 35%, p = 0.02). CONCLUSION: We strongly recommend timely transfer to an ECMO center in patients with CDH who are at risk of circulatory failure.
Asunto(s)
Oxigenación por Membrana Extracorpórea/métodos , Insuficiencia Respiratoria/terapia , Oxigenación por Membrana Extracorpórea/efectos adversos , Oxigenación por Membrana Extracorpórea/estadística & datos numéricos , Oxigenación por Membrana Extracorpórea/tendencias , Humanos , Recién Nacido , Insuficiencia Respiratoria/congénito , Insuficiencia Respiratoria/etiología , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Tasa de SupervivenciaRESUMEN
BACKGROUND: In recent years increasing survival rates of neonates with congenital diaphragmatic hernia were reported. We present the results of our collective with regard to outcome and predictors of prognosis (need for ECMO, survival). PATIENTS AND METHODS: The neonates with congenital diaphragmatic hernia treated between December 1997 and June 2001 in the university children's hospital Mannheim were included. All patients with congenital diaphragmatic hernia were treated by a defined algorithm including prenatal pulmonary maturation, surfactant immediately after birth, ""gentle ventilation"", inhaled NO, high frequency ventilation and, if necessary, ECMO. We looked at early predictors of the clinical course, e. g. need for ECMO and survival: Birth weight, oxygenation index, ventilation index, the highest and the lowest arterial oxygen and the lowest carbon dioxide partial pressures during the first 24 hours in the ECMO-centre. RESULTS: Between December 1997 and June 2001 50 neonates with congenital diaphragmatic hernia were treated (24 inborn, all of them diagnosed prenatally, 26 transferred after birth). Mean OI was 45.5 cmH2O/mmHg (no ECMO: 16.4 cmH2O/mmHg; ECMO: 62.1 cmH2O/mmHg) mean VI was 133.8 cmH2O x mmHg (no ECMO: 83.9 cmH2O x mmHg; ECMO: 156.2 cmH2O x mmHg). The survival rate was 84 %. According to our algorithm 50% of the patients were treated with ECMO, 78% of the patients treated with ECMO survived. 3 Patients were excluded by the therapy option ECMO, because of contraindications. If the patients need to be treated with ECMO, the predictors of prognosis do not allow to draw conclusions on the clinical course regarding the survival of the patients. CONCLUSION: Our algorithm allows a good survival rate in patients with congenital diaphragmatic hernia. CDH patients seem to have a benefit from transfer into an ECMO centre as early as possible or prenatally. There is no basis according our experiences to exclude patients with congenital diaphragmatic hernia from ECMO. To evaluate the predictors of prognosis regarding the question, which patients do not require ECMO, which patients have a benefit of ecmo, and which patients will die despite ecmo a nationwide cdh-register could be helpful.
Asunto(s)
Oxigenación por Membrana Extracorpórea , Hernias Diafragmáticas Congénitas , Factores de Edad , Algoritmos , Peso al Nacer , Femenino , Hernia Diafragmática/diagnóstico , Hernia Diafragmática/mortalidad , Hernia Diafragmática/cirugía , Hernia Diafragmática/terapia , Humanos , Masculino , Embarazo , Diagnóstico Prenatal , Pronóstico , Análisis de Supervivencia , Transporte de Pacientes , Resultado del TratamientoRESUMEN
We describe a 10 year old boy with organising pneumonia associated with acute Mycoplasma pneumoniae infection. The diagnosis of organising pneumonia was made by open lung biopsy and the M pneumoniae infection was proven serologically. Antibiotic and long term corticosteroid treatment resulted in steadily improving pulmonary function monitored by spirometry. The introduction of anti-inflammatory treatment with NSAIDs/immunosuppressive agents in order to spare steroids was well tolerated and resulted in further improvement of the pulmonary function. To our knowledge this is the first documented case of Mycoplasma pneumoniae associated organising pneumonia to be reported in a child.
Asunto(s)
Neumonía en Organización Criptogénica/complicaciones , Neumonía por Mycoplasma/microbiología , Antiinflamatorios no Esteroideos/uso terapéutico , Anticuerpos Antibacterianos/sangre , Biopsia/métodos , Niño , Neumonía en Organización Criptogénica/diagnóstico , Neumonía en Organización Criptogénica/tratamiento farmacológico , Humanos , Pulmón/patología , Masculino , Mycoplasma pneumoniae/inmunología , Neumonía por Mycoplasma/diagnóstico , Neumonía por Mycoplasma/tratamiento farmacológico , Espirometría/métodos , Tomografía Computarizada por Rayos X/métodosAsunto(s)
Aorta Torácica/anomalías , Estenosis Esofágica/etiología , Aorta Torácica/diagnóstico por imagen , Niño , Ecocardiografía , Estenosis Esofágica/diagnóstico , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador , Angiografía por Resonancia Magnética , Tomografía Computarizada por Rayos XRESUMEN
OBJECTIVE: To investigate the treatment of nitric oxide (NO)-induced methemoglobinemia by methylene blue (MB), riboflavin, and N-acetylcysteine (NAC) in vitro. DESIGN: Prospective, controlled in vitro study. SETTING: Research laboratory in a university hospital. PARTICIPANTS: Five healthy volunteers. INTERVENTIONS: Generation of 16% to 18% of methemoglobin in red blood cells by NO and subsequent addition of MB, riboflavin, or NAC. Simultaneous NO (32 ppm) and MB or riboflavin exposure of red blood cells. Induction of 14% to 18% of methemoglobin in red blood cells by NO, subsequent addition of MB or riboflavin, and further incubation with NO (80 ppm). MEASUREMENTS AND MAIN RESULTS: After discontinuation of NO, mean half-life for methemoglobin was significantly reduced by MB from 356 mins (controls) to 5 mins (10 microM) in a dose-dependent manner (p < .001). NAC did not alter the half-life for methemoglobin, and a reduction from 356 to 168 mins was seen for 120 microM riboflavin (p < .001). Methemoglobin formation after 3 hrs of NO exposure was 4.3%+/-0.7% in controls and 0.3%+/-0.1% with 10 microM MB (p < .001); 1 microM MB attenuated methemoglobin formation to 1.9%+/-0.1% (p < .01). With riboflavin (120 microM), methemoglobin was 2.2%+/-0.5% vs. 3.2%+/-0.6% in controls (p < .001). In the presence of high methemoglobin concentrations, further methemoglobin formation was inhibited by 1 and 10 microM MB (p < .001) and attenuated by 0.1 microM MB (p < .001) but not by riboflavin. CONCLUSIONS: In vitro, NO-induced methemoglobin formation is significantly decreased by medium (1 microM) and high (10 microM) concentrations of MB and partially by high riboflavin concentrations (120 microM). NAC and low concentrations of riboflavin do not alter methemoglobin formation.
Asunto(s)
Acetilcisteína/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Depuradores de Radicales Libres/uso terapéutico , Metahemoglobinemia/tratamiento farmacológico , Azul de Metileno/uso terapéutico , Riboflavina/uso terapéutico , Adulto , Células Cultivadas , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Eritrocitos/química , Eritrocitos/efectos de los fármacos , Humanos , Metahemoglobina/análisis , Metahemoglobina/efectos de los fármacos , Metahemoglobinemia/sangre , Metahemoglobinemia/inducido químicamente , Óxido NítricoRESUMEN
OBJECTIVE: To examine the kinetics of successful nitric oxide (NO) withdrawal in vivo and in vitro. DESIGN AND SETTING: Prospective study in a university pediatric intensive care ward and research laboratory. PATIENTS AND MATERIALS: Nineteen patients with acute respiratory distress syndrome (ARDS) or persistent pulmonary hypertension of the newborn (PPHN). Primary porcine pulmonary artery cells in vitro. INTERVENTIONS: NO inhalation and withdrawal in patients; exposure to NO donor sodium nitroprusside (SNP) and gaseous NO in vitro. MEASUREMENTS AND RESULTS: In patients: a slight, but significant, increase of oxygenation index (OI) from 4.57 +/- 0.24 cmH2O/torr (mean +/- SEM) to 4.90 +/- 0.26 cmH2O/torr after withdrawal of NO (p < 0.001). Recovery of OI (4.43 +/- 0.23 cmH2O/torr) 30 min after weaning, a significant drop after 4 h (3.72 +/- 0.17 cmH2O/ torr;p < 0.001), values restored after 12 h. In vitro: NO synthase (NOS) activity was significantly lower in SNP-incubated cells (20.0 +/- 4.0 microM/min) than in control cells (37.6 +/- 7.0 microM/ min; p < 0.05). Thirty minutes after SNP withdrawal there was NOS activity of 35.8 +/- 10.0 microM/min with a significant increase by 4 h (p < 0.05). No alteration of endothelial NOS (ENOS) mRNA expression by NO (Northern Blot). CONCLUSION: In patients there is a slight, but significant, reversible increase of OI after successful weaning from NO. In vitro, NO leads to a reversible decrease of ENOS activity on a post mRNA level, resembling clinical observations.
Asunto(s)
Broncodilatadores/farmacocinética , Endotelio Vascular/efectos de los fármacos , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico/farmacocinética , Síndrome de Dificultad Respiratoria del Recién Nacido/metabolismo , Administración por Inhalación , Animales , Northern Blotting , Broncodilatadores/administración & dosificación , Broncodilatadores/efectos adversos , Línea Celular , Niño , Preescolar , Cuidados Críticos , Cartilla de ADN , Endotelio Vascular/citología , Endotelio Vascular/metabolismo , Femenino , Citometría de Flujo , Regulación Enzimológica de la Expresión Génica , Humanos , Hipertensión Pulmonar/inducido químicamente , Lactante , Recién Nacido , Masculino , Óxido Nítrico/administración & dosificación , Óxido Nítrico/efectos adversos , Óxido Nítrico Sintasa/genética , Óxido Nítrico Sintasa/metabolismo , Estudios Prospectivos , ARN Mensajero/metabolismo , Síndrome de Dificultad Respiratoria del Recién Nacido/terapia , Síndrome de Abstinencia a Sustancias , PorcinosRESUMEN
OBJECTIVE: During nitric oxide inhalation, methemoglobinemia needs to be monitored. We compared six commercially available instruments and one manual method for methemoglobin measurements. In addition, we studied whether and to what degree methylene blue interferes with methemoglobin measurements. DESIGN: In vitro methodologic study. SETTING: Research laboratory in a university hospital. PATIENTS: Five healthy volunteers from whom red blood cells were obtained. INTERVENTIONS: Methemoglobinemia was generated in a red blood cell suspension by nitric oxide; methemoglobin was measured with six commercial instruments and one manual photometric method to calculate variation coefficients and to determine the differences between the devices. Methemoglobin was measured with and without the addition of methylene blue with two instruments. Measurements were performed immediately after the addition of methylene blue. MEASUREMENTS AND MAIN RESULTS: All six commercially available instruments had variation coefficients of <0.1 at methemoglobin concentrations of 5%, whereas the manual photometric method did not reach a variation coefficient of <0.1 at 8% of methemoglobin. Apart from two devices that measured slightly but significantly higher methemoglobin levels, all instruments measured similar values of methemoglobin when the same samples were determined simultaneously. Higher concentrations of methylene blue (10, 40, 100 microM) reduced substantially the apparent concentrations of methemoglobin. Interference by methylene blue was most pronounced at low methemoglobin levels. CONCLUSIONS: With some limitations, all commercial instruments that were tested performed adequately for the monitoring of methemoglobinemia. Methylene blue interferes with the methemoglobin measurements in a dose-dependent manner.
Asunto(s)
Hemoglobinometría/instrumentación , Metahemoglobinemia/diagnóstico , Adulto , Análisis de Varianza , Diseño de Equipo , Hemoglobinometría/métodos , Humanos , Metahemoglobinemia/inducido químicamente , Azul de Metileno/efectos adversos , Oximetría/instrumentación , Fotometría , Juego de Reactivos para Diagnóstico , Reproducibilidad de los ResultadosRESUMEN
The objective of the present study was to investigate the treatment of nitric oxide (NO)-induced methemoglobinemia by ascorbate and its consequences on red blood cell (RBC) glutathione in vitro. RBC were obtained from five healthy volunteers. The following experiments were carried out: (1) After methemoglobin generation by NO, ascorbate was added (2) RBC were simultaneously exposed to NO and ascorbate (3) Methemoglobin was generated by NO, ascorbate was added and incubation with NO continued. (1) After discontinuation of NO, the mean half life for methemoglobin was reduced from 195 min (controls) to 60 min (10 mM ascorbate) in a dose-dependent manner. (2) Methemoglobin formation after 3 h of NO exposure was 2.7 +/- 0.3% in controls and 1.8 +/- 0.1% with 10 mM ascorbate (p < 0.01). (3) Further methemoglobin formation was inhibited only by 10 mM ascorbate (p < 0.001). NO incubation did not affect RBC glutathione (86.5 +/- 19.6 and 86.5 +/- 19.6 mg/l, respectively). Treatment with 10 mM ascorbate significantly decreased glutathione (p < 0.002). In vitro, NO-induced methemoglobin formation is significantly decreased only by a high (10 mM) ascorbate concentration. Glutathione, critical for ascorbate activity, is not influenced by NO.
Asunto(s)
Ácido Ascórbico/administración & dosificación , Eritrocitos/efectos de los fármacos , Metahemoglobina/efectos de los fármacos , Metahemoglobinemia/tratamiento farmacológico , Óxido Nítrico/efectos adversos , Adulto , Análisis de Varianza , Ácido Ascórbico/farmacología , Relación Dosis-Respuesta a Droga , Eritrocitos/metabolismo , Glutatión/efectos de los fármacos , Glutatión/metabolismo , Humanos , Técnicas In Vitro , Metahemoglobina/metabolismo , Metahemoglobinemia/inducido químicamente , Oxidación-Reducción , Espectrofotometría , Factores de TiempoRESUMEN
OBJECTIVES: Methemoglobinemia is a well-known side effect of nitric oxide inhalation. We tested the hypothesis whether cardiopulmonary bypass increases methemoglobin formation by nitric oxide. DESIGN: A two-phase study: a) a controlled, prospective in vivo study of inhaled nitric oxide treatment followed by b) a second, prospective and controlled in vitro study. SETTING: Pediatric intensive care unit and research laboratory in a university hospital. PATIENTS: The in vivo study consisted of 25 patients following open-heart surgery and 19 children with acute respiratory distress syndrome (ARDS) or persistent pulmonary hypertension of the newborn. The in vitro study consisted of 20 patients with and 20 patients without cardiopulmonary bypass. INTERVENTIONS: For the in vivo study, methemoglobin measurements were taken before and after application of 20 parts per million (ppm) of nitric oxide. For the in vitro study, red blood cells of patients were incubated with 32 ppm nitric oxide before and after surgery. Methemoglobin, glutathione, adenosine triphosphate (ATP), and nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate (NADH/NADHP) concentrations were compared. MEASUREMENTS AND MAIN RESULTS: For the in vivo study, nitric oxide inhalation increased methemoglobin from 0.2 +/- 0.1% to 1.2 +/- 0.7% in patients receiving nitric oxide after open-heart surgery and from 0.2 +/- 0.1% to 0.5 +/- 0.4% in ARDS/persistent pulmonary hypertension of the newborn patients (p < .01). For the in vitro study, nitric oxide incubation of red blood cells increased methemoglobin concentration from 3.7 +/- 1.9% preoperatively to 7.4 +/- 2.4% after open-heart surgery. This increase was not observed in patients who did not undergo cardiopulmonary bypass (3.6 +/- 1.6% vs. 3.6 +/- 1.9%; p < .001). In erythrocytes of patients undergoing extracorporeal circulation, there was no difference between pre- and postoperative glutathione, ATP, and NADH/NADPH concentrations. CONCLUSIONS: Cardiopulmonary bypass is an important risk factor for methemoglobinemia when inhaled nitric oxide is applied. This risk is not secondary to diminished concentrations of energetic substrates.
Asunto(s)
Puente Cardiopulmonar/efectos adversos , Eritrocitos/metabolismo , Metahemoglobinemia/etiología , Óxido Nítrico/efectos adversos , Administración por Inhalación , Análisis Químico de la Sangre , Procedimientos Quirúrgicos Cardíacos , Niño , Preescolar , Circulación Extracorporea/efectos adversos , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Metahemoglobina/análisis , Metahemoglobinemia/inducido químicamente , Óxido Nítrico/administración & dosificación , Síndrome de Circulación Fetal Persistente/terapia , Estudios Prospectivos , Síndrome de Dificultad Respiratoria del Recién Nacido/terapiaRESUMEN
Neuropeptide Y and nitric oxide (NO) synthase are colocalized in nervous tissues. We tested the hypothesis whether or not NO might be involved in the release of neuropeptide Y. Neuropeptide Y concentration in the supernatant of PC12 rat pheochromocytoma cells, shown to express NO synthase I by immunohistochemistry, rose threefold in a time- and dose-dependent manner following sodiumnitroprusside and 3-morpholinosydnonimine (SIN-1) incubation. Neuropeptide Y mRNA expression was induced by NO-donors as a function of incubation-time. Neuropeptide Y production rose fivefold with zaprinast, an inhibitor of the phosphodiesterase V and threefold with nerve growth factor (NGF). Combined application of zaprinast and NGF did not further increase neuropeptide Y production while combination of zaprinast and sodiumnitroprusside potentiated the NO effect on neuropeptide Y release. The data suggest that NO regulates neuropeptide Y secretion of PC12 pheochromocytoma cells on the mRNA level.
Asunto(s)
Neuropéptido Y/metabolismo , Óxido Nítrico/fisiología , Feocromocitoma/metabolismo , Animales , Northern Blotting , Inhibidores Enzimáticos/farmacología , Inmunohistoquímica , Molsidomina/análogos & derivados , Molsidomina/farmacología , Factores de Crecimiento Nervioso/farmacología , Óxido Nítrico Sintasa/metabolismo , Nitroprusiato/farmacología , Células PC12 , Inhibidores de Fosfodiesterasa/farmacología , Purinonas/farmacología , ARN/biosíntesis , ARN/aislamiento & purificación , Radioinmunoensayo , Ratas , ATPasa Intercambiadora de Sodio-Potasio/antagonistas & inhibidoresRESUMEN
BACKGROUND: Pulmonary hypertension is responsible for a substantial part of perioperative and postoperative mortality and morbidity after cardiac transplantation. Treatment of right ventricular failure after increased pulmonary vascular resistance is difficult especially in infants and children. Therefore we started a preventive therapy of pulmonary hypertension after cardiac transplantation to avoid right ventricular failure and compared the results with a group of patients with conventional therapy. METHODS: Group 1 (n = 13), with transplantation from 1988 to 1991, was treated with vasodilators when symptoms of right ventricular failure developed. Group 2 (n = 19) had preventive treatment with prostaglandin E1 (PGE1), the phosphodiesterase-III inhibitor enoximone, and alkalinazation starting during weaning from cardiopulmonary bypass. RESULTS: Six patients in group 1 died; four of them as the result of right ventricular failure in the immediate postoperative course despite aggressive treatment. In group 2 there were three deaths as the results of rejection (2) and infection (1). None of these patients developed right ventricular failure (p = 0.02). Cold ischemic time, extracorporeal circulation time, and waiting time before transplantation were significantly longer in group 2. Side effects of this preventive therapy were not observed. CONCLUSIONS: We conclude that prophylactic therapy of pulmonary hypertension with vasodilators in infants and children after heart transplantation is safe and effective in preventing right ventricular failure in the postoperative course.
Asunto(s)
Cardiotónicos/uso terapéutico , Trasplante de Corazón , Hipertensión Pulmonar/prevención & control , Cuidados Intraoperatorios , Vasodilatadores/uso terapéutico , Álcalis/administración & dosificación , Álcalis/uso terapéutico , Alprostadil/administración & dosificación , Alprostadil/uso terapéutico , Gasto Cardíaco Bajo/prevención & control , Gasto Cardíaco Bajo/terapia , Puente Cardiopulmonar , Cardiotónicos/administración & dosificación , Causas de Muerte , Niño , Preescolar , Frío , Dobutamina/administración & dosificación , Dobutamina/uso terapéutico , Enoximona/administración & dosificación , Enoximona/uso terapéutico , Circulación Extracorporea , Rechazo de Injerto/etiología , Humanos , Lactante , Infecciones Oportunistas/etiología , Inhibidores de Fosfodiesterasa/administración & dosificación , Inhibidores de Fosfodiesterasa/uso terapéutico , Complicaciones Posoperatorias , Arteria Pulmonar/fisiopatología , Tasa de Supervivencia , Factores de Tiempo , Resistencia Vascular/fisiología , Vasodilatadores/administración & dosificación , Disfunción Ventricular Derecha/prevención & control , Disfunción Ventricular Derecha/terapiaRESUMEN
We evaluated the effects of asthma and cystic fibrosis on nitric oxide (NO) concentrations in the respiratory tract. NO levels in orally exhaled air and nasal gas samples were studied in 90 asthmatic patients (4-14 yrs), 67 patients with cystic fibrosis (CF) (5-32 yrs), and 68 controls (4-34 yrs). NO concentrations measured by chemiluminescene were correlated with the patient's vital capacity, forced expiratory volume in one second (FEV1) and specific airway resistance. In all groups, NO concentrations in orally-exhaled air correlated with the inhaled ambient NO (r = 0.85-0.91). At an ambient NO concentration of 0 parts per billion (ppb), asthmatic patients exhaled air with higher NO concentrations than cystic fibrosis patients and controls (8.0 +/- 6.1 ppb (n = 33); 4.9 +/- 2.6 ppb (n = 23); and 3.0 +/- 2.5 ppb (n = 37); respectively; p < 0.001). Similar results were obtained for ventilation-adjusted orally-exhaled NO. Nasal NO concentrations were lower in patients with CF (23 +/- 17 ppb) than in controls and asthmatics (96 +/- 47 and 103 +/- 64 ppb; p < 0.001). There was no relationship between nasal or oral NO and pulmonary function tests. Our results suggest that ambient NO levels influence NO concentrations in orally-exhaled air. Like adults, asthmatic children exhale more NO than their controls. Reduced nasal NO concentrations in patients with cystic fibrosis may reflect chronic epithelial cell damage or an increased mucosal barrier impeding NO diffusion into the airway.
Asunto(s)
Asma/metabolismo , Fibrosis Quística/metabolismo , Óxido Nítrico/metabolismo , Adolescente , Adulto , Pruebas Respiratorias , Estudios de Casos y Controles , Niño , Femenino , Humanos , Mediciones Luminiscentes , Masculino , Nasofaringe/metabolismo , Óxido Nítrico/análisis , Pruebas de Función Respiratoria , Tráquea/metabolismoRESUMEN
A 14 weeks old infant was admitted to the intensive care unit with life-threatening hypocalcemic-hyperphosphatemic spasms. Hypocalcemia-hyperphosphatemia was found to have been caused by feeding a high phosphate/ low calcium soy milk. The daily uptake of calcium was calculated to have been 3.3-6 mmol that of phosphate 30 mmol. The parents strongly believed that soy milk formulas were equivalent to breast milk and cow's milk formulas and lived on a strictly vegetarian diet. Therapy with calcium (at an initial dose of 2.25 mmol/kg/day) and 1.25 OH vitamin D3 (Rocaltrol, 0.25 microgram/day) normalized Ca, PO4, vitamin D and parathyroid hormone levels rapidly. Vegetarian feeding had led to life-threatening hypocalcemic hyperphosphatemic spasms in the infant. We conclude that malnutrition and false nutritional beliefs have to be included as a potential cause of early hypocalcemia in infants.
Asunto(s)
Hipocalcemia/etiología , Alimentos Infantiles/efectos adversos , Proteínas de Soja/efectos adversos , Tetania/etiología , Calcio/sangre , Dieta Vegetariana , Humanos , Hipocalcemia/sangre , Hipocalcemia/terapia , Lactante , Masculino , Necesidades Nutricionales , Fosfatos/sangre , Proteínas de Soja/administración & dosificación , Tetania/sangre , Tetania/terapia , Vitamina D/sangreRESUMEN
OBJECTIVE: Inhaled nitric oxide is a potent and selective pulmonary artery vasodilator. We studied the effects of nitric oxide inhalation in neonatal and pediatric acute respiratory distress syndrome (ARDS) patients with respect to dosage, prolonged inhalation, and weaning. DESIGN: Prospective, open-label study. SETTING: Neonatal and pediatric intensive care units of a level three university hospital. PATIENTS: Seventeen patients with severe ARDS (1 day to 6 yrs of age [mean 1.75]; oxygenation index of > 20 cm H2O/torr) were enrolled. INTERVENTIONS: To identify the optimal dosage for continuous nitric oxide inhalation, doses between 1 and 80 parts per million (ppm) of nitric oxide were tested after the patients had stabilized. Daily withdrawals of nitric oxide were made, according to predetermined criteria. MEASUREMENTS AND MAIN RESULTS: Nine neonatal and eight pediatric ARDS patients (mean Pediatric Risk of Mortality score 28.4 +/- 6.1; mortality risk 54 +/- 15%) were studied. The following variables changed within 24 hrs of nitric oxide inhalation: mean oxygenation index decreased by 56% (from 34 +/- 12 to 15 +/- 7 cm H2O/torr, p = .0004); alveolar-arterial O2 gradient decreased by 31% (from 579 +/- 71 to 399 +/- 102 torr (77.2 +/- 9.5 to 53.2 +/- 13.6 kPa), p = .0004); and mean systemic arterial pressure increased by 15% (from 49 +/- 10 to 57 +/- 12 mm Hg, p = .0029). The optimal dose of nitric oxide was 20 ppm in neonates (with additional persistent pulmonary hypertension of the newborn) and 10 ppm in pediatric patients. Prolonged inhalation (4 to 21 days) was associated with continuous improvement of oxygenation. An oxygenation index of < 5 cm H2O/torr predicted successful withdrawal, with a sensitivity of 75% and a specificity of 89%. None of the patients had to be rescued with extracorporeal membrane oxygenation and 16 of the 17 patients survived. CONCLUSIONS: Inhaled nitric oxide enhances pulmonary gas exchange, with concomitant hemodynamic stabilization, in neonatal and pediatric ARDS. Best effective doses were 10 ppm of nitric oxide in pediatric ARDS and 20 ppm in neonates. Treatment should be continued until an oxygenation index of < or = 5 cm H2O/torr is achieved. Effects on outcome need verification in larger controlled trials.